ACCURAY INCARAYEarnings & Financial Report
Accuray is a radiation therapy company that develops, manufactures, and sells radiation therapy systems to deliver treatments including stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). It is the developer of innovative technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, the latest generation TomoTherapy platform. The company is headquartered in Sunnyvale, CA, the United States. The platforms are installed in leading healthcare ...
Revenue
$127.5M
Gross Profit
$39.0M
Operating Profit
$4.2M
Net Profit
$1.1M
Gross Margin
30.6%
Operating Margin
3.3%
Net Margin
0.9%
YoY Growth
-5.0%
EPS
$0.01
ACCURAY INC Q4 FY2025 Financial Summary
ACCURAY INC reported revenue of $127.5M (down 5.0% YoY) for Q4 FY2025, with a net profit of $1.1M (down 66.8% YoY) (0.9% margin). Cost of goods sold was $88.6M, operating expenses totaled $34.7M.
Key Financial Metrics
| Total Revenue | $127.5M |
|---|---|
| Net Profit | $1.1M |
| Gross Margin | 30.6% |
| Operating Margin | 3.3% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
ACCURAY INC Q4 FY2025 revenue of $127.5M breaks down across 2 segments, led by Products at $70.7M (55.4% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Products | $70.7M | 55.4% |
| Services | $56.8M | 44.6% |
ACCURAY INC Revenue by Segment — Quarterly Trend
ACCURAY INC revenue by segment across the last 4 reported quarters, showing how each business line (such as Products and Services) has evolved quarter over quarter.
| Segment | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 |
|---|---|---|---|---|
| Products | $45.0M | $37.2M | $70.7M | $57.3M |
| Services | $57.2M | $56.8M | $56.8M | $55.9M |
ACCURAY INC Annual Revenue by Year
ACCURAY INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $458.5M).
| Year | Annual Revenue |
|---|---|
| 2025 | $458.5M |
| 2024 | $446.6M |
| 2023 | $447.6M |
| 2022 | $429.9M |
ACCURAY INC Quarterly Revenue & Net Profit History
ACCURAY INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2026 | $102.2M | -12.0% | $-13.8M | -13.5% |
| Q1 FY2026 | $93.9M | -7.5% | $-21.7M | -23.1% |
| Q4 FY2025 | $127.5M | -5.0% | $1.1M | 0.9% |
| Q3 FY2025 | $113.2M | +12.0% | $-1.3M | -1.1% |
| Q2 FY2025 | $116.2M | +8.3% | $2.5M | 2.2% |
| Q1 FY2025 | $101.5M | -2.3% | $-4.0M | -3.9% |
| Q4 FY2024 | $134.3M | +13.5% | $3.4M | 2.5% |
| Q3 FY2024 | $101.1M | -14.3% | $-6.3M | -6.3% |
Income Statement
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $101.1M | $134.3M | $101.5M | $116.2M | $113.2M | $127.5M | $93.9M | $102.2M |
| YoY Growth | -14.3% | 13.5% | -2.3% | 8.3% | 12.0% | -5.0% | -7.5% | -12.0% |
Balance Sheet
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $462.5M | $468.6M | $473.1M | $478.4M | $484.3M | $470.2M | $456.8M | $448.0M |
| Liabilities | $421.4M | $423.5M | $427.9M | $430.5M | $434.7M | $389.1M | $394.9M | $394.6M |
| Equity | $41.1M | $45.1M | $45.2M | $47.9M | $49.6M | $81.2M | $61.9M | $53.4M |
Cash Flow
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-8.1M | $9.9M | $-7.3M | $1.8M | $18.1M | $-9.7M | $12.2M | $-16.0M |